Guidance

HPV universal vaccination information for health professionals

Updated 20 June 2023

Applies to England

© Crown copyright 2023

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/hpv-vaccination-and-cervical-cancer-addressing-the-myths/hpv-universal-vaccination-information-for-health-professionals

The human papillomavirus (HPV) vaccine

The HPV vaccine is not new, it’s been used in the UK since 2008 and more than 10 million doses have been given. It’s used in over 80 countries including the US, Australia, Canada, and most of Western Europe, and more than 80 million people have been vaccinated worldwide. In 2022 the HPV vaccine will change from Gardasil to Gardasil® 9 and this HPV vaccine is already given in several other countries.

Are many parents refusing the vaccine?

Nearly 90% of parents choose to accept the HPV vaccine for their children. Most women aged 15 to 24 years in England have now been given the vaccine.

Should the vaccine be given to young people at an older age?

No. Vaccination at a younger age is more effective at preventing HPV infection. So the best time to be vaccinated is between 12 and 14 years.

Will safe sex protect young people from HPV?

No. HPV can spread by skin to skin contact. Condoms do not completely prevent the risk of infection.

How do we know the HPV vaccine works

In England, we have already seen a significant decrease in infections with the 2 main HPV types that can cause cancer (types 16 and 18).

We have also shown declines – probably due to cross-protection – in 3 other HPV types linked to cancer (types 31, 33 and 45). We expect to see even greater declines in these types (and types 52 and 58) with the implementation of Gardasil® 9.

The number of precancerous lesions in the cervix has already fallen by over 70% since the programme began in Scotland. We have also seen large declines in the number of genital warts in young people.

The UK programme has already contributed to preventing future deaths from cervical cancer. We expect it to eventually prevent hundreds of cancer deaths every year.

Frequency of side effects reported after HPV compared to other vaccines

To date, the number of reports to the Medicines and Healthcare Products Regulatory Agency (MHRA) of suspected side effects for HPV vaccines is not unusual. The overwhelming majority relate to mild conditions commonly seen when you vaccinate teenagers (for example injection site reactions such as redness, pain, swelling; headache, nausea, fatigue; immediate faints due to needle phobia).

The American Academy of Pediatrics (AAP) advice on HPV vaccine

The AAP is an organisation of around 50,000 US doctors who fully support the HPV programme.

The American College of Pediatrics is an organisation of around 500 religious doctors who broke away from AAP over the issue of gay adoption. They believe that pre-marital abstinence is most effective, but they still favour offering HPV vaccination because of potential risk beyond an individual’s control (including sexual assault and the infection of one’s future spouse).

Does the vaccine cause serious long-term illnesses?

No. When almost everyone is vaccinated, it’s not surprising that some people go on to develop illnesses some time after vaccination – that does not mean that the vaccine caused the illness. It’s easy to understand why the family might blame the vaccine, particularly if the onset of illness is poorly defined.

In 2016, Danish researchers showed that girls who reported illnesses from the HPV vaccine were more likely to have seen the doctor in the period before vaccination. This suggests that some of these conditions may have already been developing before vaccination.

A number of authorities, including the Centers for Disease Control and Prevention in the US, the World Health Organization, and the European Medicines Agency have looked carefully at all the cases that have been reported and concluded that there is no credible evidence of a link between HPV vaccine and a range of chronic illnesses.

Do HPV vaccines cause premature ovarian failure?

Premature ovarian failure is rare but occurs naturally in adolescent girls. The number of cases reported does not exceed what might be expected in the absence of vaccination.

In 2013, the MHRA conducted a large study in the UK which showed no link between HPV vaccine and illnesses such as chronic fatigue syndrome and fibromyalgia.

Over the past few years several studies based in different countries have found no evidence of a link between the HPV vaccine and a range of serious and chronic illnesses (see references below).

Extensive reviews of vaccine safety have concluded that evidence does not support a link between HPV vaccine and the development of a range of chronic illnesses.

The product insert mentions a number of serious and chronic conditions – including death – does that mean that the vaccine causes these conditions?

No. Although the US package insert lists a range of reported illnesses, these are included regardless of any established link with the vaccine. Similarly, in the spirit of openness, the EU product insert also mentions conditions reported after vaccination across the world – even in isolated cases – but this does not mean that the vaccine was responsible.

Further information

HPV vaccination programme on GOV.UK.

HPV vaccine on NHS.UK.

The HPV vaccine: beating cervical cancer.

Jo’s Trust.

References

  1. Vichnin M and others. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatric Infectious Disease Journal. 2015 Sep;34(9):983-91.

  2. Grimaldi-Bensouda L and others. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine. 2014 Apr;275(4):398-408.

  3. Pellegrino P and others. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmunity Reviews. 2014 Jul;13(7):736-741

  4. Klein NP and others. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Archives of Pediatrics and Adolescent Medicine. 2012 Dec;166(12):1140-8.

  5. Donegan K and others. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013 Oct 9;31(43):4961-7.

  6. Gee J and others. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26;29(46):8279-84.

  7. Cameron RL and others. Adverse event monitoring of the human papillomavirus vaccines in Scotland. Journal of Internal Medicine. 2016 Apr;46(4):452-7.

  8. Arnheim-Dahlström L and others. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013 Oct 9;347:f5906.

Back to top